Alzheimer's Disease Molecular Subtype Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease (AD) are limited, with only four FDA-approved medications for managing cognitive impairment, and there is a need for effective methods to prevent, treat, or delay the progression of the disease, particularly due to its heterogeneous nature and the challenge of predicting disease progression among patients.
Innovation Solution
Identification of five molecular subtypes of AD with distinct molecular signatures, network regulator genes, and matched mouse models, allowing for the prediction of clinical features, diagnostic signatures, and identification of key regulator genes and candidate drugs for treatment, as well as stratification of patient populations for suitable treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FDA-approved medications are used to treat Alzheimer's disease, then cognitive impairment management is provided, but treatment effectiveness is limited due to disease heterogeneity
Solution Approach 1:
The patent segments Alzheimer's disease into five distinct molecular subtypes (A, B1, B2, C1, C2) based on gene expression profiles and molecular signatures. This segmentation allows for subtype-specific treatment strategies rather than a one-size-fits-all approach, directly addressing the limitation of current medications that cannot effectively handle disease heterogeneity.
Solution Approach 2:
The patent changes the classification parameters from clinical symptoms alone to molecular signatures including gene expression patterns, network regulator genes, and pathway activities. This parameter change enables more precise patient stratification into molecular subtypes, improving treatment effectiveness by matching therapies to specific molecular profiles rather than just clinical presentations.
2Measurement precision
If molecular subtyping is implemented to address disease heterogeneity, then treatment precision is improved, but diagnostic complexity increases
Solution Approach 1:
The patent develops a universal molecular classification framework that can be applied across different Alzheimer's disease patients to identify one of five predefined subtypes. This universal system uses a core set of molecular markers and network regulator genes that can be measured through standardized assays, making the complex molecular diagnostics more accessible and implementable in clinical settings.
Solution Approach 2:
The patent creates molecular signature profiles for each of the five subtypes that serve as reference templates. These copied molecular patterns can be used to classify new patients by comparing their gene expression profiles against the established subtype signatures, simplifying the diagnostic process while maintaining high precision.
3Adaptability or versatility
If patient stratification into molecular subtypes is performed, then personalized treatment identification is enabled, but time and resources for analysis increase
Solution Approach 1:
The patent performs preliminary molecular subtyping and identifies key network regulator genes and pathway activities early in the diagnostic process. By establishing the molecular subtype classification beforehand, clinicians can quickly match patients to appropriate treatment candidates without needing to perform exhaustive analyses at the time of treatment selection, thus reducing analysis time while maintaining personalized treatment matching.
Data Source
AI summary
Disclosed herein are methods for identifying the neuronal and neurodegenerative phenotypes affected by and identified in Alzheimer's Disease, characterized as Alzheimer's Disease subtypes, methods for identifying drugs effective for treating Alzheimer's Disease subtypes, and drugs useful in treating Alzheimer's Disease subtypes.